Animal studies have demonstrated the efficacy of endothelial progenitor cells (EPCs) in preventing left ventricular (LV) remodelling following myocardial infarction (MI). Preliminary human studies are underway, yet no studies have demonstrated efficacy in combination with standard medical therapy, i.e. angiotensin-converting enzyme (ACE) inhibitors and β-blockers. Nude rats underwent left anterior descending coronary artery ligation to induce MI. Animals were randomised to receive no treatment (MI, n=5), quinapril 200 mg/L + metoprolol 2 g/L (ACE/BB, n=5), two million EPCs intravenously (EPC, n=5)or both (ACE/BB + EPC [n=5]), then sacrificed after two weeks treatment. ACE/BB resulted in a 75% reduction in fibrosis in the region remote from the MI (p<0.05), but EPC therapy had little effect here. Conversely, EPC therapy induced neovascularisation at the peri-infarct rim, thereby preventing peri-infarct apoptosis by 81% (p<0.05). Acting via different but complementary mechanisms, the combination of ACE/BB + EPCs resulted in a greater overall improvement in LV function on echocardiography than either therapy alone. Clinical trials using stem cell therapy in conjunction with standard medical treatment are warranted.
Introduction
Myocardial ischaemia remains a leading cause of heart failure, which affects nearly five million patients in the United States alone, with approximately 550,000 new cases diagnosed there each year. 1 The socio-economic burden of heart failure is projected to increase worldwide. Angiotensinconverting enzyme (ACE) inhibitors and beta adrenergic receptor blockers (β-blockers) remain the cornerstone of medical therapy for post myocardial infarction (MI) heart failure, because of their demonstrated efficacy in reducing mortality and preventing deterioration in left ventricular (LV) function. [2] [3] [4] [5] [6] [7] Among their various modes of action, ACE inhibitors and β-blockers have been shown to reduce collagen deposition in the extracellular matrix. 8, 9 Recent studies have highlighted the potential therapeutic role for adult bone marrow-derived stem cells in preventing LV dysfunction following MI. [10] [11] [12] [13] Various cell populations have been used in animal studies, all showing clear improvement in LV function. [14] [15] [16] Skeletal myoblast therapy has been shown to have an additive effect with ACE inhibitors (ACE-I) when the two therapies are combined. 17 To date, however, no stem cell therapy has been shown to be effective in combination with the standard regimen of post-MI therapy i.e.ACE inhibition plus β-blockade.
We have previously shown 18 that there exists in the adult human bone marrow a population of cells with the phenotypic and functional characteristics of embryonic angioblasts.These cells are contained within the CD34+ fraction of bone marrow, and are variously known as angioblasts or endothelial progenitor cells (EPCs). When human CD34+ cells, which contain the angioblast fraction, are administered to athymic rats post-MI, they induce neovascularisation of the peri-infarct rim, which prevents apoptosis of cardiomyocytes in this region. This limits infarct expansion and improves LV function. 18 The renin-angiotensin and adrenergic systems are involved in expansion of the extracellular matrix (ECM) and collagen deposition at sites remote to the infarct, and blockade of these systems has been shown to prevent this. 8, 9 In contrast, angioblast/EPC therapy exerts most of its beneficial effects at the peri-infarct region. We designed this study to determine whether the use of both approaches together is additive on improvement in LV function.
Methods and materials

Animal model
Male Rowett (mu/mu) athymic nude rats aged 10 weeks were anaesthetised, intubated and ventilated.A left anterior thoracotomy was performed, the pericardial sac was incised and the left anterior descending (LAD) coronary artery was ligated. Two days after LAD ligation, animals underwent baseline transthoracic echocardiography and were then randomised into four treatment groups: group 1 (MI, n=5) received no treatment, group 2 (ACE/BB, n=5) received quinapril 200 mg/L and metoprolol 2 g/L in drinking water, group 3 (EPCs, n=5) received 2 million human CD34+ cells intravenously once, group 4 (ACE/BB + EPCs, n=5) received quinapril, metoprolol and EPCs. These doses of quinapril 19 and metoprolol 20 have been shown to prevent LV remodelling on their own. Two weeks following randomisation, animals underwent repeat echocardiography and were sacrificed. The left ventricle was sectioned transversely, fixed in neutral buffered formalin and embedded in paraffin for subsequent light microscopic evaluation. All experimental procedures were approved by the Columbia University Institute for Animal Care and Use Committee.
Purification and characterisation of cytokine-mobilised human CD34+ cells
Single-donor leukopheresis products were obtained from humans treated with recombinant G-CSF 10 mg/kg (Amgen, CA) subcutaneously daily for four days. Donors were healthy individuals undergoing standard institutional procedures of bone marrow mobilisation, harvesting and isolation for allogeneic stem cell transplants. Mononuclear cells were separated by Ficoll-Hypaque, and highly-purified CD34+ cells (>98% positive) were obtained using magnetic beads coated with anti-CD34 monoclonal antibody (mAb) (Miltenyi Biotech, CA). We have previously shown that 6-12% of these mobilised human CD34+ cells are phenotypically angioblasts, as demonstrated by positive staining for CD34, GATA-2 and bright staining for CD117, 21 and that administration of two million human G-CSF mobilised CD34+ cells results in neovascularisation of the peri-infarct myocardium, thereby preventing LV remodelling. 18
Histopathology and immunohistochemistry
The accumulation of collagenous matrix in the myocardium of the non-infarct zone was assessed in sections obtained at the mid-papillary level of the left ventricle, stained with Masson's modified trichrome, 22 using computer-assisted image analysis. Sections from the mid-left ventricle were digitally captured and then loaded onto a Pentium III IBM computer. An area of blue on a trichromestained section was selected for its colour range and the proportional area of tissue with this range of colour was then quantified. Calculation of the proportional area stained blue (matrix) was then determined using image analysis (AIS, Analytical imaging Station Version 6.0, Ontario, Canada). Immunohistochemical staining for blood vessels was performed by an immunoperoxidase technique, using an Avidin/Biotin Blocking Kit, a rat-absorbed biotinylated anti-mouse IgG, and a peroxidase-conjugate (all Vector Laboratories Burlingame, CA). Induction of neovascularisation at two weeks was measured by performing quantitative analysis of capillaries at the peri-infarct rim containing >6 contiguous vWF positive endothelial lining cells. Capillaries had a mean lumen diameter of 0.053 mm + 0.004. Data are expressed as the number of capillaries per high power field (X400).
For detection of apoptosis, we used the terminal deoxynucleotidyl transferase deoxyuridine triphosphate nick end labeling (TUNEL) method of DNA end-labelling mediated by dexynucleotidyl transferase (TdT) (Boehringer Mannheim, Mannheim, Germany). The tissue sections were digested with Proteinase K (10 ug/ml in Tris/HCL) and then washed and incubated with 50 ul of the TUNEL reaction mixture (TdT and fluoresceinlabelled dUTP) and incubated in a humid atmosphere. For negative controls, TdT was eliminated from the reaction mixture.The sections were then incubated for 30 minutes with an antibody specific for fluorescein-conjugated alkaline phosphatase (AP) (Boehringer Mannheim, Mannheim, Germany).The TUNEL stain was visualised with a substrate system in which nuclei with DNA fragmentation stain blue (BCIP/NBT substrate system, DAKO, Carpinteria, CA). An anti-troponin I antibody (Accurate Chemicals, CT) was incubated overnight. Sections were then treated with an antirabbit IgG, followed by a biotin-conjugated secondary antibody for 30 minutes (Sigma, Saint Louis, Missouri).An avidin-biotin complex (Vector Laboratories, Burlingame, CA) was then added for an additional 30 minutes and the myocytes were visualised brown following exposure in DAB solution mixture (Sigma, Saint Louis, Missouri). Results were expressed as the mean number of apoptotic myocytes per high power field (HPF). All tissues were assessed with the examiner masked to the experimental groups.
Analysis of myocardial function
Echocardiographic studies were performed using a high frequency transducer (SONOS 5500, Hewlett Packard, Andover, MA). 2D images were obtained in the short axis view at mid-papillary level. Cardiac dimensions were measured using the leading edge method of the American Society of Echocardiography. Fractional shortening (FS%) was calculated according to the formula: FS% = (EDD -ESD) / EDD X 100 where EDD = end-diastolic diameter, ESD = end-systolic diameter, as previously described. 23 Three consecutive cardiac cycles were analysed for all animals, and the mean of these figures recorded. All studies were analysed offline by a single cardiologist blinded to the treatment group and timing of the studies.
Statistical analysis
All data are presented as mean + SEM. ANOVA with Fischer's post hoc test was used to compare treatment groups.A p value < 0.05 was considered statistically significant. SPSS version 11 for Mac OSX was used for all statistics.
Results
Neovascularisation
Treatment with EPCs resulted in significant neovascularisation of the peri-infarct zone, with a 2.5fold increase in the number of vessels in the periinfarct zone, compared with saline-treated animals (p=0.001).Treatment with ACE/BB in the absence of EPCs had no effect on the number of vessels in the peri-infarct area. Moreover, combining ACE/BB with EPCs resulted in no difference in vessel number compared with EPC therapy alone. (Figures 1 and 2A) .
Apoptosis
EPC treatment following MI resulted in an 81% reduction in the number of apoptotic cardiomyocytes at the peri-infarct rim (p<0.05). Standard treatment with ACE-I and β-blocker in the absence of EPC therapy did not reduce the number of apoptotic myocytes.The combination of standard therapy and EPCs did not result in a further reduction in apoptosis than EPC therapy alone. (Figures  1 and 2B) .
Extracellular matrix deposition
MI resulted in substantial deposition of collagenous extracellular matrix in the region remote from the MI, as indicated by collagenous ECM comprising 4.2 + 1.4% of the myocardium in the posterior wall of the LV. EPC therapy had no effect on ECM in this area.ACE inhibition and β-blockade resulted in sig-nificant reduction in this ECM deposition in the posterior wall (p<0.05), regardless of whether EPC therapy was also used or not. (Figure 2C ).
LV function
Following MI, LV function was the same in all groups (data not shown). In the untreated animals, there was a continued 36 + 9% deterioration in fractional shortening (FS) from day 2 to day 16 post-MI. Standard therapy with ACE-Is and β-blockers prevented this ongoing loss of LV function (-1 + 13%). EPC therapy tended to improve FS (10 + 7%). Combination of the standard treatments of ACE inhibition and β-blockade with EPCs resulted in an overall improvement of 53 + 37% (p<0.05), which was greater than either treatment alone. Figure 2D .
Discussion
This study has two novel findings. Firstly,ACE inhibition and β-blockade act predominantly in the region remote from the MI to reduce LV remodelling, with no effect on neovascularisation or apoptosis at the peri-infarct rim. In contrast, EPC therapy acts at the peri-infarct region to induce new vessel formation, reduce apoptosis and thereby reduce pathological ventricular remodelling by a completely different mechanism. Secondly, combined treatment with EPCs and ACE inhibition/β-blockade results in a greater overall improvement in LV function than either alone. As we have shown previously, 18 administration of human CD34+ EPCs on day 2 following MI resulted in significant neovascularisation of the peri-infarct zone at two weeks, and this effect was shown to last for at least 15 weeks. In this study, we have shown a 2.5-fold increase in the number of vessels in this area following EPC therapy.This effect is independent of the effects of ACE inhibitors and β-blockers, and occurs in the presence or absence of these agents, suggesting that they have little or no role in chemotaxis of EPCs or in the formation of blood vessels.A reduction in apoptosis accompanies this neovascularisation ( Figure 1B) . ACE inhibition/β-blockade does not result in significant reduction in myocyte apoptosis at the peri-infarct rim. Interestingly, the addition of ACE inhibition/β-blockade to EPC therapy tends to abrogate the reduction in apoptotic myocytes induced by EPC therapy alone.This suggests that some degree of angiotensin II and/or adrenergic stimulation is necessary for optimal effect of neovascularisation in reducing apoptosis. The mechanism by which addition of ACE inhibition/β-blockade to EPC induced neovascularisation reduces the number of apoptotic cardiomyocytes is unclear. Further studies of the mechanism of this observation are warranted.
MI has been shown to be associated with increased ECM deposition in the regions remote from the infarct zone, one of the hallmarks of LV remodelling, 24 ACE-I and β-blocker therapy results in an approximately 75% reduction in posterior wall collagen compared with untreated MI, but EPC therapy did not alter the amount of collagen PAPER Figure 1 Blood vessels (A, C, E, G) and apoptotic cardiomyocytes (B, D, F, H) at the peri-infarct rim. Untreated MI animals (A, B) had small numbers of vessels, stained brown for the endothelial specific antigen vWF (arrow heads), and high numbers of apoptotic cardiomyocytes with blue nuclei from TUNEL stain (arrows).ACE/BB group (C,D) also had low numbers of vessels and frequent apoptotic cardiomyocytes. EPC treated animals had many more vessels and a resultant reduction in numbers of apoptotic nuclei.Addition of AC/BB to EPC had no effect on vessel number and did not reduce the number of apoptotic nuclei Figure  2C ).This suggests that EPC therapy predominantly works via reduction in apoptosis at the peri-infarct rim, thereby preventing LV remodelling at the edge of the MI.ACE-I and β-blocker therapy act to reduce ECM deposition in the areas remote from the infarct zone, thus preventing LV remodelling in this region. Echocardiography demonstrates continued loss of LV function from day 2 to day 16 post-MI in untreated subjects. The reduction in adverse remodelling seen with ACE-I/β-blocker therapy resulted in prevention of deterioration of LV function by echocardiography, similar to the effect seen with EPC therapy. Combined treatment with both EPCs and drugs showed an enhanced functional recovery, with FS improving following the initial period of LV dysfunction.
Conclusion
ACE inhibition with β-blockade, the cornerstone of current post-MI treatment, and EPC therapy, an innovative approach to post-MI therapy, reduce pathological LV remodelling following MI when used alone. The combination of these therapies results in a greater overall improvement in LV function than either therapy alone, and they appear to act via different mechanisms. Future clinical studies of EPC therapy, in combination with standard treatments, following MI are warranted. 
